207 related articles for article (PubMed ID: 20177049)
1. Insufficient evidence for association of NOD2/CARD15 or other inflammatory bowel disease-associated markers on GVHD incidence or other adverse outcomes in T-replete, unrelated donor transplantation.
Nguyen Y; Al-Lehibi A; Gorbe E; Li E; Haagenson M; Wang T; Spellman S; Lee SJ; Davidson NO
Blood; 2010 Apr; 115(17):3625-31. PubMed ID: 20177049
[TBL] [Abstract][Full Text] [Related]
2. NOD2/CARD15 single nucleotide polymorphism 13 (3020insC) is associated with risk of sepsis and single nucleotide polymorphism 8 (2104C>T) with herpes viruses reactivation in patients after allogeneic hematopoietic stem cell transplantation.
Jaskula E; Lange A; Kyrcz-Krzemien S; Markiewicz M; Dzierzak-Mietla M; Jedrzejczak WW; Czajka P; Mordak-Domagala M; Lange J; Gronkowska A; Nowak J; Warzocha K; Hellmann A; Kowalczyk J; Drabko K; Gozdzik J; Mizia S;
Biol Blood Marrow Transplant; 2014 Mar; 20(3):409-14. PubMed ID: 24345423
[TBL] [Abstract][Full Text] [Related]
3. NOD2/CARD15 variants are not a risk factor for clinical outcome after nonmyeloablative allogeneic stem cell transplantation.
van der Straaten HM; Paquay MM; Tilanus MG; van Geloven N; Verdonck LF; Huisman C
Biol Blood Marrow Transplant; 2011 Aug; 17(8):1231-6. PubMed ID: 21215810
[TBL] [Abstract][Full Text] [Related]
4. Polymorphism of interleukin-23 receptor gene but not of NOD2/CARD15 is associated with graft-versus-host disease after hematopoietic stem cell transplantation in children.
Gruhn B; Intek J; Pfaffendorf N; Zell R; Corbacioglu S; Zintl F; Beck JF; Debatin KM; Steinbach D
Biol Blood Marrow Transplant; 2009 Dec; 15(12):1571-7. PubMed ID: 19896081
[TBL] [Abstract][Full Text] [Related]
5. Both donor and recipient NOD2/CARD15 mutations associate with transplant-related mortality and GvHD following allogeneic stem cell transplantation.
Holler E; Rogler G; Herfarth H; Brenmoehl J; Wild PJ; Hahn J; Eissner G; Schölmerich J; Andreesen R
Blood; 2004 Aug; 104(3):889-94. PubMed ID: 15090455
[TBL] [Abstract][Full Text] [Related]
6. Genetic variations of interleukin-23R (1143A>G) and BPI (A645G), but not of NOD2, are associated with acute graft-versus-host disease after allogeneic transplantation.
Wermke M; Maiwald S; Schmelz R; Thiede C; Schetelig J; Ehninger G; Bornhäuser M; Wassmuth R
Biol Blood Marrow Transplant; 2010 Dec; 16(12):1718-27. PubMed ID: 20541026
[TBL] [Abstract][Full Text] [Related]
7. Effect of NOD2/CARD15 variants in T-cell depleted allogeneic stem cell transplantation.
Granell M; Urbano-Ispizua A; Aróstegui JI; Fernández-Avilés F; Martínez C; Rovira M; Rius J; Plaza S; Gaya A; Navarro A; Talarn C; Carreras E; Monzó M; Montserrat E; Yagüe J
Haematologica; 2006 Oct; 91(10):1372-6. PubMed ID: 17018387
[TBL] [Abstract][Full Text] [Related]
8. The role of genetic variants of NOD2/CARD15, a receptor of the innate immune system, in GvHD and complications following related and unrelated donor haematopoietic stem cell transplantation.
Holler E; Rogler G; Brenmoehl J; Hahn J; Greinix H; Dickinson AM; Socie G; Wolff D; Finke J; Fischer G; Jackson G; Rocha V; Hilgendorf I; Eissner G; Marienhagen J; Andreesen R
Int J Immunogenet; 2008 Aug; 35(4-5):381-4. PubMed ID: 18976442
[TBL] [Abstract][Full Text] [Related]
9. Mapping MHC haplotype effects in unrelated donor hematopoietic cell transplantation.
Petersdorf EW; Malkki M; Horowitz MM; Spellman SR; Haagenson MD; Wang T
Blood; 2013 Mar; 121(10):1896-905. PubMed ID: 23305741
[TBL] [Abstract][Full Text] [Related]
10. Single nucleotide polymorphisms in the NOD2/CARD15 gene are associated with an increased risk of relapse and death for patients with acute leukemia after hematopoietic stem-cell transplantation with unrelated donors.
Mayor NP; Shaw BE; Hughes DA; Maldonado-Torres H; Madrigal JA; Keshav S; Marsh SG
J Clin Oncol; 2007 Sep; 25(27):4262-9. PubMed ID: 17724347
[TBL] [Abstract][Full Text] [Related]
11. Recipient NOD2/CARD15 variants: a novel independent risk factor for the development of bronchiolitis obliterans after allogeneic stem cell transplantation.
Hildebrandt GC; Granell M; Urbano-Ispizua A; Wolff D; Hertenstein B; Greinix HT; Brenmoehl J; Schulz C; Dickinson AM; Hahn J; Rogler G; Andreesen R; Holler E
Biol Blood Marrow Transplant; 2008 Jan; 14(1):67-74. PubMed ID: 18158963
[TBL] [Abstract][Full Text] [Related]
12. HLA-mismatched unrelated donors are a viable alternate graft source for allogeneic transplantation following alemtuzumab-based reduced-intensity conditioning.
Mead AJ; Thomson KJ; Morris EC; Mohamedbhai S; Denovan S; Orti G; Fielding AK; Kottaridis PD; Hough R; Chakraverty R; Linch DC; Mackinnon S; Peggs KS
Blood; 2010 Jun; 115(25):5147-53. PubMed ID: 20371745
[TBL] [Abstract][Full Text] [Related]
13. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
[TBL] [Abstract][Full Text] [Related]
14. Donor Clonal Hematopoiesis and Recipient Outcomes After Transplantation.
Gibson CJ; Kim HT; Zhao L; Murdock HM; Hambley B; Ogata A; Madero-Marroquin R; Wang S; Green L; Fleharty M; Dougan T; Cheng CA; Blumenstiel B; Cibulskis C; Tsuji J; Duran M; Gocke CD; Antin JH; Nikiforow S; DeZern AE; Chen YB; Ho VT; Jones RJ; Lennon NJ; Walt DR; Ritz J; Soiffer RJ; Gondek LP; Lindsley RC
J Clin Oncol; 2022 Jan; 40(2):189-201. PubMed ID: 34793200
[TBL] [Abstract][Full Text] [Related]
15. A novel technique for NOD2/CARD15 genotyping using PCR-SSP.
Mayor NP; Shaw BE; Keshav S; Madrigal JA; Marsh SG
J Immunol Methods; 2007 Oct; 327(1-2):82-7. PubMed ID: 17719603
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of NOD2/CARD15 variants in HLA-identical sibling hematopoietic stem cell transplantation: effect on long-term outcome is confirmed in 2 independent cohorts and may be modulated by the type of gastrointestinal decontamination.
Holler E; Rogler G; Brenmoehl J; Hahn J; Herfarth H; Greinix H; Dickinson AM; Socié G; Wolff D; Fischer G; Jackson G; Rocha V; Steiner B; Eissner G; Marienhagen J; Schoelmerich J; Andreesen R
Blood; 2006 May; 107(10):4189-93. PubMed ID: 16424393
[TBL] [Abstract][Full Text] [Related]
17. The importance of graft cell composition in outcome after allogeneic stem cell transplantation in patients with malignant disease.
Svenberg P; Wang T; Uhlin M; Watz E; Remberger M; Ringden O; Mattsson J; Uzunel M
Clin Transplant; 2019 Jun; 33(6):e13537. PubMed ID: 30873642
[TBL] [Abstract][Full Text] [Related]
18. Superior survival associated with transplantation of matched unrelated versus one-antigen-mismatched unrelated or highly human leukocyte antigen-disparate haploidentical family donor marrow grafts for the treatment of hematologic malignancies: establishing a treatment algorithm for recipients of alternative donor grafts.
Drobyski WR; Klein J; Flomenberg N; Pietryga D; Vesole DH; Margolis DA; Keever-Taylor CA
Blood; 2002 Feb; 99(3):806-14. PubMed ID: 11806980
[TBL] [Abstract][Full Text] [Related]
19. Comparable outcome of alternative donor and matched sibling donor hematopoietic stem cell transplant for children with acute lymphoblastic leukemia in first or second remission using alemtuzumab in a myeloablative conditioning regimen.
Kennedy-Nasser AA; Bollard CM; Myers GD; Leung KS; Gottschalk S; Zhang Y; Liu H; Heslop HE; Brenner MK; Krance RA
Biol Blood Marrow Transplant; 2008 Nov; 14(11):1245-52. PubMed ID: 18940679
[TBL] [Abstract][Full Text] [Related]
20. Multiple single-nucleotide polymorphism-based risk model for clinical outcomes after allogeneic stem-cell transplantation, especially for acute graft-versus-host disease.
Kim DD; Yun J; Won HH; Cheng L; Su J; Xu W; Uhm J; Gupta V; Kuruvilla J; Messner HA; Lipton JH
Transplantation; 2012 Dec; 94(12):1250-7. PubMed ID: 23169244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
